CONTACT

Direction d'équipe

Christophe CAUX
christophe.caux@lyon.unicancer.fr

Cheney D - 3ème étage
Centre Léon Bérard
CAUX Christophe
Chef d'équipe
DEPIL Stéphane
Praticien hospitalier (CLB)
stephane.depil@lyon.unicancer.fr
DORE Jean-François
BACHELOT Thomas
Praticien hospitalier CLB   
thomas.bachelot@lyon.unicancer.fr
DUBOIS Bertrand
MICHALLET Marie-Cécile
MENETRIER-CAUX Christine
PUISIEUX Isabelle
BENDRISS-VERMARE Nathalie
VALLADEAU-GUILEMOND Jenny
RODRIGUEZ Céline
DOFFIN-MARVIE Anne-Claire
MOUDOMBI Lyvia
ONODI Fanny
Ingénieure CLB    
fanny.onodi@lyon.unicancer.fr
POUJOL Dominique
Technicienne CLB    
dominique.poujol@lyon.unicancer.fr
BERTHET Justine
Ingenieure CLB    
justine.berthet@lyon.unicancer.fr
DI ROIO Anthony
BOSSENEC Marion
COUILLAULT Coline
BONAVENTURA Paola
MUSSARD Julie
Voir les objectifs et projets Voir les publications

Principaux financements
INSERM
CNRS
Université Claude Bernard Lyon I
Institut National du Cancer (INCa)
Association pour la Recherche sur le Cancer (ARC)
Ligue Nationale contre le Cancer (Comités de l’Ain, de l’Ardèche, de la Drôme, du Puy de Dôme, du Rhône, de Savoie et de Saône et Loire)
Agence Nationale pour la Recherche (ANR)
Région Auvergne Rhône-Alpes
Lyon Biopole
Laboratoire d'Excellence (LabEx) DevWeCan (Grand Emprunt)
Fondation pour la Recherche Médicale (FRM) 

Principales collaborations nationales
Institut Gustave Roussy (Villejuif) / Laurence ZITVOGEL
INSERM U851 (Lyon) / Jacqueline MARVEL et Thierry WALZER
Institut de Recherche Thérapeutique IRT UN Unité INSERM 892, Centre de Recherche en Cancérologie Nantes-Angers (Nantes) / Henri VIE
Institut Curie (Paris) / Sebastian AMIGORENA, Vassili SOUMELIS, …
Université Pierre et Marie Curie (Paris) / Benoit SALOMON et Gilles MARODON
INSERM U631 (CIML, Marseille) / Marc DALOD et Bernard MALISSEN
Laboratoire d'Immunologie des Tumeurs, Centre de Recherche en Cancérologie de Marseille (Marseille) / Daniel OLIVE
INRA (Jouy en Josas) / Nicolas BERTHO et Isabelle SWARTZ-CORNIL
Institut de Biologie Structurale (Grenoble) / Franck FIESCHI
Institut de Génétique Moléculaire de Montpellier (Montpellier) / Marc PIECHAZYCK
Société BASF (Lyon) / Valérie ANDRE et Nicolas BECHETOILLE
Groupe Hospitalier Pitié Salpêtrière (Paris) / Dr Jean-Baptiste BACHET
Groupe Hospitalier Universitaire Ambroise Paré (Paris) / Pr Jean-François EMILE
Hôpital de la TIMONE / Dr Sébastien SALAS
Institut Bergonié (Bordeaux) / Pr Jean Michel COINDRE, Dr Isabelle HOSTIEN, Dr Frederic CHIBON
ImmunID Technologies (Grenoble) / N. PASQUAL
Université d’Auvergne/CHU (Clermont Ferrand) / Marc BERGER
INSERM U1035 (Bordeaux) / Jean-Max PASQUET
CNRS 8619-IBBMC (Orsay) / Michel LEPOIVRE
USR3010 – LJC CNRS (Lyon) Equipe Mechano-genetics of the cell / Françoise ARGOUL
Faculté de medicine, U895 (Nice) Cell death differentiation and cancer / Dr Patrick AUBERGER

Principales collaborations internationales
Société ROCHE (Penzberg, Allemagne) Carola RIES
Société GlaxoSmithKline (Brentford, UK/Agnes Goetschel)
Brad NELSON (Victoria British Columbia, Canada)
PHARMAMAR (Carlos GALMARINI, colmenar viejo, espagne)




OBJECTIFS

Le système immunitaire est l’une des principales barrières protégeant notre organisme du développent tumoral. Cependant, le système immunitaire peut aussi dans certaines circonstances faciliter le développement tumoral par des mécanismes encore peu connus. Notre objectif est donc d’identifier ces mécanismes impliquées dans la subversion du système immunitaire par les cellules cancéreuses et de développer des stratégies basées sur l’identification de l’immunogénicité des différentes formes de mort cellulaire et par la réactivation des mécanismes d’immuno-surveillance. Les modèles tumoraux sur lesquels nous travaillons sont le cancer du sein et de l’ovaire et le mélanome.

PROJETS

PUBLICATIONS

2018

 

  1. Faure-Dupuy S, Vegna S, Aillot L, Dimier L, Esser K, Broxtermann M, Bonnin M, Bendriss-Vermare N, Rivoire M, Passot G, Lesurtel M, Mabrut J-Y, Ducerf C, Salvetti A, Protzer U, Zoulim F, Durantel D, Lucifora J. (2018) Characterisation of Pattern Recognition Receptors (PRR) expression and functionality in liver primary cells and derived cell lines. Journal of Innate Immunity In press

  2. I. Monteiro, S. Vigano, M. Faouzi, I. Treilleux, O. Michielin, C. Ménétrier-Caux, C. Caux, P. Romero, L and de Leval.(2018) CD73 expression and clinical significance in human metastatic melanoma. Oncotarget In Press

  3. Gourdin N, Bossennec M, Rodriguez C, Vigano  S, Jandus C, Mâchon C, Bauché D, Faget J, Durand I, Chopin N, Tredan O, Marie J, Dubois B, Guitton J, Romero P, Caux C *, Ménétrier-Caux C *.(*co-last authorship). (2018) Autocrine Adenosine regulates tumor polyfunctional CD73+CD4+ effector T cells devoid of immune checkpoints Cancer Research In Press.

  4. Aillot L, Bonnin M, Ait-Goughoulte M, Bendriss-Vermare N, Maadadi S, Dimier L, Subic M, Scholtes C, Najera I, Zoulim F, Lucifora J, Durantel D. Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. Antimicrob Agents Chemother. 2018 Mar 27;62(4).

  5. Small M*, Treilleux I*, Couillault C*, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B*, Honnorat J*, Desestret V* (*co-last authorship). (2018). Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol. Jan 3. doi: 10.1007/s00401-017-1802-y.

  6. Hacini F., Gomez de Agüero M., Kanjarawi R., Moro-Sibilot L., Le Luduec J.B., Macari C., Boschetti G., Bardel E., Langella P., B. Dubois* & D. Kaiserlian* (*co-last authorship) (2018). Intestinal dendritic cell licensing through TLR4 is required for oral tolerance in allergic contact dermatitis. J Allergy Clin Immunol., 141(1): 163-170.

 

2017

  1. Combes A, Camosseto V, N’Guessan P, Argüello RJ, Mussard J, Caux C, Bendriss-Vermare N, Pierre P & and Gatti E (2017). BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells. Nature Comm. 8(1):913

  2. Mazet J, Michallet MC. (2017). Neutrophil: an infiltrated agent with new antitumor skills. Med Sci (Paris) 33(8-9): 744-47.

  3. Richaud M and Bendriss-Vermare N. (2017). Cancer immunotherapy via systemic RNA delivery to dendritic cells. Med Sci (Paris). 33(10):852-856.

  4. Seillet C and Dubois B. (2017) Infiltrated B cells promote pancreatic ductal adenocarcinoma. Med Sci (Paris) 33(10): 859-862.

  5. Vanacker H, Vetters J, Moudombi L, Caux C, Janssens S, Michallet MC. (2017) Emerging role of the Unfolded Protein Response in Tumor Immunosurveillance. Trends Cancer. 3(7): 491-505.

  6. Hirsch I, Janovec V, Stranska R, Bendriss-Vermare N. (2017) Cross Talk between Inhibitory Immunoreceptor Tyrosine-Based Activation Motif-Signaling and Toll-Like Receptor Pathways in Macrophages and Dendritic Cells. Front Immunol. Apr 7;8:394.

  7. Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, Albaret MA, Ortiz-Cuaran S, Thomas E, Colombe A, Py C, Gadot N, Michot JP, Fayette J, Viari A, Van den Eynde B, Goudot P, Devouassoux-Shisheboran M, Puisieux A, Caux C, Zrounba P, Lantuejoul S, Saintigny P. (2017) The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 28(8): 1934-41.

  8. Shekarian T, Valsevia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle A. (2017) Pattern Recognition Receptors: Immune Targets to Enhance Cancer Immunotherapy. Ann Oncol. 28(8): 1756-66.

 

2016

  1. Le KS, Thibult ML,Just-Landi S, Pastor S, Gondois-Rey F, Granjeaud S, Broussais F, Bouabdallah R, Colisson R, Caux C, Ménétrier-Caux C, Leroux D, Xerri L and Olive D (2016). Follicular lymphoma B cells generate functional regulatory T cells via ICOS/ICOSL pathway and are inhibited by intratumoral Tregs Cancer Res. in press.
  2. PAN H, Gazarian A, Dubernard JM, Belot A, Michallet MC*, Michallet M* ( *co-last authorship). Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages and Potential Strategies. Frontiers in Immunology in press.Le Luduec JB, Debeer S, Piras F, Andréoni C, Boudet F, Laurent P, Kaiserlian D, Dubois B. (2016) Indradermermal vaccination with un-adjuvanted sub-unit vaccines triggers skin innate immunity and confers protective respiratory immunity in domestic swine. Vaccine 34: 914-922.
  3. Moro-Sibilot L, This S, Blanc P, Sanlaville A, Sisirak V, Bardel E, Boschetti G, Bendriss-Vermare N, Defrance T, Dubois B, Kaiserlian D. Plasmacytoid dendritic cells are dispensable for non-infectious intestinal IgA responses in vivo.  Eur J Immunol. 2016 Feb;46(2):354-9.
  4. Duraes FV, Lippens C, Steinbach K, Dubrot J, Brighouse D, Bendriss-Vermare N, Issazadeh-Navikas S, Merkler D, Hugues S. (2015) pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation. J Autoimmun. 2016 Feb;67:8-18.

2015

  1. Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N’Kodia A, Bardin C, Rigal C, Pérol D, Caux C*, Ménétrier-Caux C* ( *co-last authorship) (2015) Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. OncoImmunology 5(3):e1100791.
  2. Dezutter-Dambuyant C, Durand I, Alberti L, Bendriss-Vermare N, Valladeau-Guilemond J, Duc A, Magron A,  Morel AP, Sisirak V, Rodriguez C, Cox D, Olive D, Caux C. (2015) A novel regulation of PD-1 Ligands on Mesenchymal Stromal Cells through MMP-mediated proteolytic cleavage. OncoImmunology 5(3):e1091146.
  3. Ghirelli C, Reyal F, Jeanmougin M, Zollinger R, Sirven P, Michea P, Caux C, Bendriss-Vermare N, Donnadieu MH, Caly M, Fourchotte V, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X, Soumelis V. (2015). Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. Cancer Res. 75(14):2775-87.
  4. Trédan O≠, Ménétrier-Caux C≠, Ray-Coquard I≠, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot, Rigal C, N’Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY*, Caux C* (≠co-first authorship, * co-last authorship).  (2015) ELYPSE-7: A randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol. 26(7):1353-62.
  5. Dupuis-Maurin V, Brinza L, Baguet J, Plantamura E, Schicklin S, Chambion S, Macari C, Tomkowiak M, Deniaud E, Leverrier Y, Marvel J*, Michallet MC*. (*co-last authorship) (2015) Overexpression of the transcription factor Sp1 activates the OAS-RNAse L-RIG-I pathway. Plos One. 10(3):e0118551.
  6. Pan H, Gazarian A, Buff S, Solla F, Gagnieu MC, Leveneur O, Watrelot-Virieux D, Morisset S, Sobh M, Michallet MC, Roger T, Dubernard JM, Michallet M. (2015) Oral cyclosporine A in neonatal swines for transplantation studies. Immunopharmacology and Immunotoxicology. 37(1):19-25.
  7. Mathieu AL, Verronese E, Rice GI,Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD,  Butte M, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zabot M, Balme B,Viel S, Bienvenu J, Cochat P, van Der Burg M, Caux C, Kemp H, Rouvet I, Malcus C, Crow YJ,Fabien N, Ménétrier-Caux C, De Villartay JP, Walzer T and Belot A. (2015) PRKDC mutations associated with immunodeficiency, granuloma and AIRE-dependent auto-immunity. J Allergy Clin Immunol. 135(6):1578-88.e5.

2014

  1. Dutour A, Josserand V, Jury D, Guillermet S, Decouvelaere AV, Chotel F, Pointecouteau T, Rizo P, Coll JL, Blay JY. (2014) Targeted imaging of αvβ3 expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: A potential tool to reduce incomplete surgical resection. Bone. 62:71-8.
  2. Deauvieau F, Ollion V, Doffin AC, Verronese E., Durand I, Ghittoni R, Marvel J, Walzer T, Vie H., Perrot I., Goutagny N., Caux C*. and Valladeau-Guilemond J*. (2014) Human natural killer cells promote tumor cell-derived antigen cross presentation by dendritic cells through cytokine production. Int J Cancer 136(5):1085-94. *co-senior authors
  3. Zannetti C, Parroche P, Panaye M, Roblot G, Gruffat H, Manet E, Debaud AL, Plumas J, Vey N, Caux C, Bendriss-Vermare N, Hasan UA. TLR9 transcriptional regulation in response to double-stranded DNA viruses. J Immunol. 2014 Oct 1;193(7):3398-408.
  4. Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, Vu Manh T-P, Sanchez C, Savoret J, Perrot I, Doffin AC, Fossum E, Bechlian D, Chabannon C, Bogen B, Asselin-Paturel C, Shaw M, Soos T, Caux C, Valladeau-Guilemond J*, Dalod M*. (2014) Human XCR1+ DC derived in vitro from CD34+ progenitors closely resemble blood DC including by their adjuvant responsiveness, contrary to monocyte-derived DC. J Immunol. 193(4):1622-35.*co-senior authors

2013

  1. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. (2013). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 123:2447-2463.
  2. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N. (2013). Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73:4629-4640
  3. El Sayadi H, Pissaloux D, Alberti L, Tabone-Eglinger S, Ranchere D, Decouvelaere AV, Tabone E, Ray-Coquard I, Caux C, Fayette J, Blay JY.  (2013) Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. Target Oncol. 8:261–269
  4. Bachet JB, Tabone-Eglinger S, Dessaux S, Besse A, Brahimi-Adouane S, Emile JF, Blay JY, Alberti L. (2013). Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples. PLoS One. 8:e61103
  5. Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I,  Clapisson  G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Ménétrier-Caux C, Blay JY. (2013) CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer 49:1080-1089.
  6. Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, and Bendriss-Vermare N.  (2013) Breast cancer-derived TGF-b and TNF-a compromise IFN-a production by tumor-associated plasmacytoid dendritic cells. Int J Cancer. 133:771-778.
  7. Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, and Ménétrier-Caux C. (2013) ICOS is associated with poor prognosis through immuno-suppressive CD4 T cell amplification by plasmacytoid DC in breast tumours. OncoImmunology 2:e23185
  8. Sisirak V, Faget J, Vey N, Blay JY, Ménétrier-Caux C, Caux C and Bendriss-Vermare N.  (2013) Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients OncoImmunology 2:e22338.
  9. Tredan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C and Ménétrier-Caux C. (2013). Patients with metastatic breast cancer leading to CD4+ T cell Lymphopenia have poor outcome. Eur J Cancer 49:1673-1682.2012

2012 

  1. Caux C. and Zitvogel L. Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Targeted Oncol.  7:1-2, 2012.
  2. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting Pattern Recognition Receptors in cancer immunotherapy. Targeted Oncol. 7:29-54, 2012.
  3. Labidi-Galy S.I., Treilleux I., Goddard-Léon S., Combes J.D., Blay J.Y., Ray-Coquard I., Caux C., and Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology, 1(3):379-81, 2012.
  4. Manuel M, Tredan O, Bachelot T, Clapissson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY and Ménétrier-Caux C. Lymphopenia Combined with low TCR Diversity (divpenia) predicts poor Overall Survival in Metastatic Breast Cancer Patient. OncoImmunology, 1(4):433-42, 2012.
  5. Marabelle A,Caux C. Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. Blood. 2012 Nov 29;120(23):4454-5. doi: 10.1182/blood-2012-09-455105.
  6. Ménétrier-Caux C, Faget J, Biota C, Gobert M, Blay JY and Caux C. Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. OncoImmunology, 1(5):759-61, 2012.
  7. Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C and Zou W. Targeting regulatory T cells. Targeted Oncol. 7:15-28, 2012.
  8. Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S and Puisieux A. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. Plos Genetics. 8(5): e1002723, 2012.
  9. Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Ménétrier-Caux C, Blay JY CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer 2012.
  10. Ray-Coquard I, Chauvin F., Leblanc E.  Caux C., Hoarau H., Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F. Le PAIR-gynécologie : recherche multi/interdisciplinaire en cancérologie gynécologique. Les problèmes à résoudre en 2012. Bull Cancer. 99(4):479-498, 2012.
  11. Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-Dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C. Patients with metastatic breast cancer leading to CD4(+) T cell lymphopaenia have poor outcome. Eur J Cancer. 2012 Dec 19.
  12. Segura E., Valladeau-Guilemond J., Donnadieu MH, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med. 209:653-60, 2012.

2011

  1. Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Menetrier-Caux C, Tredan O, Goddard-Leon S, Pin JJ, Mignotte H, Barthelemy-Dubois C, Caux C, Lebecque S, Blay JY. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer. 11:213-23, 2011.
  2. Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, Minard-Colin V, Poirier-Colame V, Chaba K, Flament C, Baud V, Authier H, Kerdine-Römer S, Pallardy M, Cremer I, Peaudecerf L, Rocha B, Valteau-Couanet D, Gutierrez JC, Nunès JA, Commo F, Bonvalot S, Ibrahim N, Terrier P, Opolon P, Bottino C, Moretta A, Tavernier J, Rihet P, Coindre JM, Blay JY, Isambert N, Emile JF, Vivier E, Lecesne A, Kroemer G, Zitvogel L. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 17:700-7, 2011.
  3. Faget J., Biota C., Bachelot T., Gobert M., Treilleux I., Goutagny N., Durand I., Léon-Goddard S.,  Blay J.Y., Caux C. and Ménétrier-Caux C. Early detection of tumor cells by innate immune cells leads to Treg recruitment through CCL22 production by tumor cells. Cancer Res. 71:6143-52, 2011.
  4. Gougelet A, Perez J, Pissaloux D, Besse A, Duc A, Decouvelaere AV, Ranchere-Vince D, Blay JY, Alberti L. miRNA Profiling: How to Bypass the Current  Difficulties in the Diagnosis and Treatment of Sarcomas. Sarcoma. 2011:1-14, 2011.
  5. Labidi-Galy SI, Ray-Coquard I, Sisirak V, Treilleux I, Meeus P, Mithieux F, Bajard A, Combes JD, Gobert M, Faget J, Guastalla JP, Tredan O, Ménétrier-Caux C, Caux C, Blay JY and Bendriss-Vermare N.Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 171:5423-34, 2011.
  6. Labidi-Galy S.I., Faget J., Treilleux I., Ménétrier-Caux C., Caux C., and Bendriss-Vermare N. Immunologie du cancer de l’ovaire : de la théorie à la thérapeutique. "Cancer de l’ovaire" Edition 2, (Edition : Springer), chapter book, pp 613-626, 2011.
  7. Perez J., Bardin C., Rigal C., Besse A., Rousseau R., and Dutour A. Anti MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. Anticancer Res. 31(9):2813-20, 2011.
  8. Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, Bowman EP, Trinchieri G, Dubois B,  Kaiserlian D, Lira SA, Puisieux A, Blay JY, Caux C, and Bendriss-Vermare N. CCR6/CCR10-mediated plasmacytoid dendritic cells recruitment to inflamed epithelia following instruction in lymphoid organs. Blood. 118(19):5130-40, 2011.

BREVET: Antibodies directed against ICOS and uses thereof. Filed May 2011, n° EP11305385.5. Inventors: JULIEN FAGET, MÉNÉTRIER-CAUX CHRISTINE, JACQUES NUNES, DANIEL OLIVE, CAUX CHRISTOPHE

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :